Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...

The US Food and Drug Administration (FDA) has approved a shorter infusion time for ocrelizumab (Ocrevus) for patients with relapsing or primary progressive multiple sclerosis (MS), the company has ...

An FDA-approved multiple sclerosis drug that requires 2.5 hours for the first infusion and 3.5 hours for subsequent doses might be able to shorten its duration to 10 minutes, its maker said July 14.

BILLINGS - Staff from St. Vincent Healthcare met at their Regional Neuroscience Center for the grand opening of their brand new state-of-the-art Multiple Sclerosis Infusion Center. Doctors, patients ...

– Approval based on data from the randomized, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional Ocrevus dosing regimen – – Shorter infusion time will further improve the ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

CUSM expands into Riverside with a neurology clinic offering Parkinson’s and MS care, infusion therapy to slow progression, and appointments in 1–2 weeks.

Multiple sclerosis (MS) is a disease that looks different in everyone who has it—and you may know more people who have it than you think. According to Thomas Shoemaker, MD, a RUSH neurologist and MS ...

Kavita Nair, PhD, discusses integrating neurology and pharmacy services to improve MS care coordination and reduce treatment delays.

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...